A treatment combining Vidaza and infusions of donor white blood cells may be effective in myelodysplastic syndromes patients who relapse after stem cell transplantation, according to results of a small Phase 2 clinical trial conducted in Germany.
In addition, the study authors found that patients who had a complete response to the combination therapy experienced significantly longer overall survival than those who did not.
Dr. Thomas Schroeder of Heinrich Heine University in Duesseldorf, Germany, presented the clinical trial findings at the 2011 American Society of Hematology (ASH) conference in San…
Preliminary results of a Phase 1/2 trial indicate that treatment with low-dose Clolar during an extended, alternate day treatment schedule may be effective in high-risk myelodysplastic syndromes patients who no longer respond to Vidaza.
Dr. Thorsten Braun of the Avicenne Hospital in Bobigny, France, presented the trial results during an oral session at the 2011 meeting of the American Society of Hematology (ASH) earlier this week.
Patients who fail Vidaza (azacitidine) treatment typically have poor prognoses (see the related Beacon news).
Previous studies have shown that Clolar…
This year’s American Society of Hematology (ASH) 2011 took place Saturday, December, 10, through yesterday in San Diego. This article summarizes the myelodysplastic syndromes-related highlights from Monday and yesterday.
Day 3
Monday was a busy day in terms of presentations related to myelodysplastic syndromes (MDS). There were several sessions with oral presentations throughout the day and a poster session in the evening.
The day began with a session about genetic alterations in MDS. During the session, researchers presented the latest findings on how alterations in patients’ genes and proteins may…
Results of an analysis show that early stem cell transplantation with reduced-intensity chemotherapy provides a survival benefit for older patients with higher-risk myelodysplastic syndromes, but not for those with lower-risk disease.
The study authors concluded that early transplantation is not an appropriate treatment strategy for older, lower-risk patients unless quality of life is significantly impaired.
The findings were presented at the 2011 American Society of Hematology (ASH) annual meeting in San Diego on Sunday.
Donor stem cell transplantation is currently the only available cure for myelodysplastic syndromes (MDS). Patients undergo chemotherapy…
The American Society of Hematology (ASH) 2011 annual meeting is currently being held in San Diego. This article will summarize the myelodysplastic syndromes-related highlights from Saturday, the first full day of the conference, and Sunday, the second day of the meeting.
Day 1
Saturday started off with an education session on myelodysplastic syndromes (MDS) that consisted of three talks. The program was repeated in the afternoon.
The day ended with a large poster session, during which study results from hundreds of blood disorder-related studies were displayed on big posters…